{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:07:49Z","timestamp":1793120869277,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":383,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["U01CA261841-01"],"award-info":[{"award-number":["U01CA261841-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["R01CA249016-01"],"award-info":[{"award-number":["R01CA249016-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["R01CA272601-01"],"award-info":[{"award-number":["R01CA272601-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["U01CA232382"],"award-info":[{"award-number":["U01CA232382"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Systems"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.cels.2024.04.003","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T10:40:47Z","timestamp":1716201647000},"page":"510-525.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["To modulate or to skip: De-escalating PARP inhibitor maintenance therapy in ovarian cancer using adaptive therapy"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4484-8823","authenticated-orcid":false,"given":"Maximilian A.R.","family":"Strobl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Gallaher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Robertson-Tessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gatenby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wenham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip K.","family":"Maini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Damaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-4383","authenticated-orcid":false,"given":"Alexander R.A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cels.2024.04.003_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.maturitas.2015.01.015","article-title":"PARP inhibitors: A new era of targeted therapy","volume":"81","author":"Tangutoori","year":"2015","journal-title":"Maturitas"},{"key":"10.1016\/j.cels.2024.04.003_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.12.002","article-title":"PARP inhibitors in ovarian cancer","volume":"73","author":"Franzese","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.cels.2024.04.003_bib3","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","article-title":"PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells","volume":"29","author":"Noordermeer","year":"2019","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.cels.2024.04.003_bib4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","author":"D\u2019Andrea","year":"2018","journal-title":"DNA Repair"},{"key":"10.1016\/j.cels.2024.04.003_bib5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.cels.2024.04.003_bib6","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.cels.2024.04.003_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/978-1-60327-492-0_20","article-title":"Epidemiology of ovarian cancer","volume":"472","author":"Permuth-Wey","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.cels.2024.04.003_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cels.2024.04.003_bib9","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cels.2024.04.003_bib10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cels.2024.04.003_bib11","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1200\/JCO.2020.38.15_suppl.6002","article-title":"Final overall survival (OS) results from SOLO2\/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation","volume":"38","author":"Poveda","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cels.2024.04.003_bib12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cels.2024.04.003_bib13","doi-asserted-by":"crossref","first-page":"S613","DOI":"10.1016\/j.annonc.2020.08.950","article-title":"Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y)\u00a0follow-up (f\/u) from SOLO1","volume":"31","author":"Banerjee","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cels.2024.04.003_bib14","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cels.2024.04.003_bib15","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.annonc.2022.02.222","article-title":"The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2\/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer","volume":"33","author":"Francis","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cels.2024.04.003_bib16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1634\/theoncologist.2017-0485","article-title":"Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations","volume":"23","author":"Moore","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.cels.2024.04.003_bib17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11523-016-0435-8","article-title":"An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib","volume":"11","author":"Mateo","year":"2016","journal-title":"Target. Oncol."},{"key":"10.1016\/j.cels.2024.04.003_bib18","series-title":"Lynparza (Olaparib) Capsules [Prescribing Information]","year":"2017"},{"key":"10.1016\/j.cels.2024.04.003_bib19","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cels.2024.04.003_bib20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cels.2024.04.003_bib21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/nrc2013","article-title":"Cancer as an evolutionary and ecological process","volume":"6","author":"Merlo","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cels.2024.04.003_bib22","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrc.2017.69","article-title":"Classifying the evolutionary and ecological features of neoplasms","volume":"17","author":"Maley","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cels.2024.04.003_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/clpt.2012.243","article-title":"Without therapeutic drug monitoring, there is no personalized cancer care","volume":"93","author":"Beumer","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cels.2024.04.003_bib24","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1111\/bcp.14032","article-title":"Why maximum tolerated dose?","volume":"85","author":"Stampfer","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cels.2024.04.003_bib25","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1158\/1078-0432.CCR-15-1295","article-title":"Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example","volume":"22","author":"Sachs","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cels.2024.04.003_bib26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/459508a","article-title":"A change of strategy in the war on cancer","volume":"459","author":"Gatenby","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.cels.2024.04.003_bib27","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","article-title":"Adaptive therapy","volume":"69","author":"Gatenby","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.cels.2024.04.003_bib28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41571-020-0411-1","article-title":"Integrating evolutionary dynamics into cancer therapy","volume":"17","author":"Gatenby","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cels.2024.04.003_bib29","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.84263","article-title":"A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation","volume":"12","author":"West","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.cels.2024.04.003_bib30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s43856-022-00110-x","article-title":"Spatial structure impacts adaptive therapy by shaping intra-tumoral competition","volume":"2","author":"Strobl","year":"2022","journal-title":"Commun Med. (Lond.)"},{"key":"10.1016\/j.cels.2024.04.003_bib31","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-17-2649","article-title":"Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies","volume":"78","author":"Gallaher","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.cels.2024.04.003_bib32","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1038\/s41467-017-01516-1","article-title":"Spatial competition constrains resistance to targeted cancer therapy","volume":"8","author":"Bacevic","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cels.2024.04.003_bib33","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s41559-021-01428-w","article-title":"A theoretical analysis of tumour containment","volume":"5","author":"Viossat","year":"2021","journal-title":"Nat. Ecol. Evol."},{"key":"10.1016\/j.cels.2024.04.003_bib34","doi-asserted-by":"crossref","first-page":"327ra24","DOI":"10.1126\/scitranslmed.aad7842","article-title":"Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer","volume":"8","author":"Enriquez-Navas","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cels.2024.04.003_bib35","article-title":"Testing Adaptive Therapy Protocols using Gemcitabine and Capecitabine on a Mouse Model of Endocrine-Resistant Breast Cancer","author":"Seyedi","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.cels.2024.04.003_bib36","doi-asserted-by":"crossref","first-page":"8915","DOI":"10.2147\/CMAR.S339787","article-title":"Is the fixed periodic treatment effective for the tumor system without complete information?","volume":"13","author":"Wang","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.cels.2024.04.003_bib37","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.3390\/cancers13215262","article-title":"Optimizing adaptive therapy based on the reachability to tumor resistant subpopulation","volume":"13","author":"Wang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cels.2024.04.003_bib38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ebiom.2019.09.023","article-title":"Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma","volume":"48","author":"Smalley","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cels.2024.04.003_bib39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41559-023-02255-x","article-title":"Drug dependence in cancer is exploitable by optimally constructed treatment holidays","volume":"8","author":"Maltas","year":"2024","journal-title":"Nat. Ecol. Evol."},{"key":"10.1016\/j.cels.2024.04.003_bib40","article-title":"Adaptive therapy achieves long-term control of chemotherapy resistance in high grade ovarian cancer","author":"Hockings","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.cels.2024.04.003_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.76284","article-title":"Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes","volume":"11","author":"Zhang","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.cels.2024.04.003_bib42","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41467-017-01968-5","article-title":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cels.2024.04.003_bib43","first-page":"15","article-title":"Budget Impact of Adaptive Abiraterone Therapy for Castration-Resistant Prostate Cancer","volume":"14","author":"Mason","year":"2021","journal-title":"Am. Health Drug Benefits"},{"key":"10.1016\/j.cels.2024.04.003_bib44","doi-asserted-by":"crossref","first-page":"188503","DOI":"10.1016\/j.bbcan.2021.188503","article-title":"Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer","volume":"1875","author":"Zhang","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.cels.2024.04.003_bib45","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nrc4029","article-title":"The mathematics of cancer: Integrating quantitative models","volume":"15","author":"Altrock","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cels.2024.04.003_bib46","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nrclinonc.2015.204","article-title":"Computational oncology-mathematical modelling of drug regimens for precision medicine","volume":"13","author":"Barbolosi","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cels.2024.04.003_bib47","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/s41591-021-01558-5","article-title":"Digital twins for predictive oncology will be a paradigm shift for precision cancer care","volume":"27","author":"Hernandez-Boussard","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cels.2024.04.003_bib48","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.annonc.2023.08.008","article-title":"Treatment of evolving cancers will require dynamic decision support","volume":"34","author":"Strobl","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cels.2024.04.003_bib49","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/wsbm.1343","article-title":"Mathematical models of breast and ovarian cancers","volume":"8","author":"Botesteanu","year":"2016","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"10.1016\/j.cels.2024.04.003_bib51","article-title":"Antifragile therapy","author":"West","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cels.2024.04.003_bib68","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cels.2024.04.003_bib69","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01196-x","article-title":"VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status","volume":"14","author":"Bizzaro","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cels.2024.04.003_bib54","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","article-title":"CA-125 ELImination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: Results from the phase II CHIVA trial","volume":"26","author":"You","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cels.2024.04.003_bib55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13014-015-0465-x","article-title":"A proliferation saturation index to predict radiation response and personalize radiotherapy fractionation","volume":"10","author":"Prokopiou","year":"2015","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.cels.2024.04.003_bib56","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijrobp.2021.05.132","article-title":"Forecasting Individual Patient Response to Radiotherapy in Head and Neck Cancer with a Dynamic Carrying Capacity Model","volume":"111","author":"Zahid","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.cels.2024.04.003_bib52","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-23-2040","article-title":"Mathematical Model-Driven Deep Learning Enables Personalized Adaptive Therapy","author":"Gallagher","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.cels.2024.04.003_bib53","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.3390\/cancers13122880","article-title":"Are Adaptive Chemotherapy Schedules Robust? A Three-Strategy Stochastic Evolutionary Game Theory Model","volume":"13","author":"Dua","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cels.2024.04.003_bib57","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s12967-020-02613-4","article-title":"Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy","volume":"18","author":"Sheta","year":"2020","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.cels.2024.04.003_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2001110","article-title":"How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient","volume":"15","author":"Hansen","year":"2017","journal-title":"PLoS Biol."},{"key":"10.1016\/j.cels.2024.04.003_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12123556","article-title":"Modifying adaptive therapy to enhance competitive suppression","volume":"12","author":"Hansen","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.cels.2024.04.003_bib60","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/psp4.13029","article-title":"A dynamic model of the intestinal epithelium integrates multiple sources of preclinical data and enables clinical translation of drug-induced toxicity","volume":"12","author":"Gall","year":"2023","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.cels.2024.04.003_bib61","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","article-title":"Model of chemotherapy-induced myelosuppression with parameter consistency across drugs","volume":"20","author":"Friberg","year":"2002","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.cels.2024.04.003_bib62","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40262-018-0714-x","article-title":"Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients","volume":"58","author":"Zhou","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.cels.2024.04.003_bib63","doi-asserted-by":"crossref","first-page":"eabm7212","DOI":"10.1126\/sciadv.abm7212","article-title":"Measuring competitive exclusion in non\u2013small cell lung cancer","volume":"8","author":"Farrokhian","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.cels.2024.04.003_bib64","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1086\/401873","article-title":"Quantitative Laws in Metabolism and Growth","volume":"32","author":"von Bertalanffy","year":"1957","journal-title":"Q.\u00a0Rev. Biol."},{"key":"10.1016\/j.cels.2024.04.003_bib65","first-page":"513","article-title":"XXIV. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies","volume":"115","author":"Gompertz","year":"1825","journal-title":"Philos. Trans. R. Soc. Lond."},{"key":"10.1016\/j.cels.2024.04.003_bib66","series-title":"An Introduction to Statistical Modelling","author":"Krzanowski","year":"2010"},{"key":"10.1016\/j.cels.2024.04.003_bib67","series-title":"LMFIT: Non-Linear Least-Square Minimization and Curve-Fitting for Python","author":"Newville","year":"2014"}],"container-title":["Cell Systems"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405471224001182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405471224001182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:28:54Z","timestamp":1762622934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405471224001182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2405471224001182"],"URL":"https:\/\/doi.org\/10.1016\/j.cels.2024.04.003","relation":{},"ISSN":["2405-4712"],"issn-type":[{"value":"2405-4712","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"To modulate or to skip: De-escalating PARP inhibitor maintenance therapy in ovarian cancer using adaptive therapy","name":"articletitle","label":"Article Title"},{"value":"Cell Systems","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cels.2024.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}